肺表面活性物质联合NCPAP治疗新生儿呼吸窘迫综合症中的临床观察

Observation the clinical effect of NCPAP and pulmonary surfactant in newborn with respiratory distress syndrome(a report of 30 cases)

目的：探讨鼻塞式气道正压通气（NCPAP）联合肺表面活性物质（固尔苏）治疗早产儿呼吸窘迫综合征的临床疗效及护理方法。方法：给30例患呼吸窘迫综合征的早产儿行气管插管，经气管内滴入肺表面活性物质固尔苏每次100～200mg／kg，然后拔出插管，连接NCPAP装置，给予NCPAP呼吸支持治疗。结果：30例患儿在固尔苏给药后5min呼吸窘迫明显缓解。其中16例经NCPAP给氧1h后，改用面罩给氧，10例NCPAP给氧2h后，改用面罩给氧，并逐步撤氧。仅4例死亡。结论：对早产儿呼吸窘迫综合症而言，NCPAP联合肺表面活性物质能迅速有效地改善患儿临床症状，提高了患儿的抢救成活率，且缩短了早产儿吸氧时间，减少了早产儿视网膜病变的发生率。另外，正确细致的观察和护理是治疗成功的关键。

Objective：To observe the clinical effect by nasal continuous positive airway pressure （NCPAP） and pulmonary surfactant （Curosurf） in newborn with respiratory distress syndrome. Methods：30 cases of newborn with respiratory distress syndrome were treated by Curosurf （100 -200 mg/kg, every times） and then were given breath support by NCPAP. Results： The symptoms and signs of respiratory distress in all cases had an evidence meliorate. After using NCPAP lh and 2 h, there were 16 cases and 10 cases altering veil oxygen respectively, and only 4 cases death of all. Conclusions- Using NCPAP and pulmonary surfactant are of efficacy and safety in newborn with respiratory distress syndrome, and improving the survival rate, and shorting the time of breath oxygen, and decreasing the incidence rate of retinopathy of prematurely （ROP）. The correct nursing is the key of successful treatment.